Zealthy Review
Online GLP-1 care centered on insurance navigation, brand-name prescriptions and cash-pay semaglutide options.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Quick Verdict
Online GLP-1 care centered on insurance navigation, brand-name prescriptions and cash-pay semaglutide options.
Who it's for: Zealthy is a fit for adults who want online support pursuing brand-name GLP-1 coverage through insurance or who want to compare a cash-pay semaglutide option. Its public weight-loss page emphasizes insurance coordination, clinician access and digital care tools. The displayed $25–$151 monthly range covers two materially different paths: the lower end depends on insurance coverage, while the $151 monthly cash-pay equivalent is tied to a three-month purchase. It is less suitable for readers who need a single, clearly published month-to-month all-in price before starting intake.
Bottom line: Zealthy pairs online weight-management care with insurance-navigation support and a cash-pay path. Its displayed $25–$151 monthly range is useful for comparison, but the endpoints carry different insurance and commitment conditions; confirm the exact medication, covered benefit, recurring fee, dose and renewal terms before paying.
- Insurance-navigation support for brand-name GLP-1s
- Cash-pay semaglutide option is publicly described
- Online care, refills and progress tools
- Lowest advertised price depends on insurance
- Cash-pay semaglutide rate requires a three-month purchase
- No single month-to-month all-in rate on the reviewed page
Pros & Cons In Detail
Zealthy Pricing
Telehealth ads often advertise a low headline price that's the clinic's program fee, not the medication. Here's how the two line items break down at Zealthy.
| Program / Membership Fee | Varies by insurance and plan; no separate fee stated |
| Medication Cost (From) | From $25 – $151/mo |
Zealthy advertises FDA-approved GLP-1 options from $25/month when insurance coverage applies and cash-pay semaglutide from $151/month on a three-month purchase. The $25 insurance figure and $151 three-month-plan monthly equivalent are not one universal all-in price; confirm the medication, membership, dose, up-front commitment and out-of-pocket total during intake.
Who Zealthy Is For
Zealthy is a fit for adults who want online support pursuing brand-name GLP-1 coverage through insurance or who want to compare a cash-pay semaglutide option. Its public weight-loss page emphasizes insurance coordination, clinician access and digital care tools. The displayed $25–$151 monthly range covers two materially different paths: the lower end depends on insurance coverage, while the $151 monthly cash-pay equivalent is tied to a three-month purchase. It is less suitable for readers who need a single, clearly published month-to-month all-in price before starting intake.
Adults seeking online GLP-1 care with insurance-navigation support or cash-pay semaglutide options.
Signature Programs
- ›Insurance navigation for brand-name GLP-1s
- ›Cash-pay semaglutide option
- ›Online clinician care and refills
- ›Optional coaching and progress tracking
Medication Formulary
The Bottom Line
Zealthy pairs online weight-management care with insurance-navigation support and a cash-pay path. Its displayed $25–$151 monthly range is useful for comparison, but the endpoints carry different insurance and commitment conditions; confirm the exact medication, covered benefit, recurring fee, dose and renewal terms before paying.
With an editor score of 4.0 / 5 across cost, experience, and trust, Zealthy is one of the specialty options in the glp-1 weight loss category we cover.
See how Zealthy compares in our full glp-1 weight loss rankings, or read the Best Telehealth GLP-1 Providers guide. Our methodology explains how we score each provider.
Frequently Asked Questions
- Wilding et al., NEJM 2021 (STEP 1) · Semaglutide 2.4 mg produced 14.9% mean weight loss versus 2.4% with placebo at 68 weeks in the STEP 1 trial.
- Jastreboff et al., NEJM 2022 (SURMOUNT-1) · Tirzepatide 15 mg produced 20.9% mean weight loss versus 3.1% with placebo at 72 weeks in SURMOUNT-1.
RxNotebook is an editorial publication, not a medical practice. We are not affiliated with the cited studies; source material does not endorse the providers shown. This is general information, not medical advice.